المؤلفون: Edurne Arriola, Ramón García Gómez, Pilar Diz, Margarita Majem, Maite Martínez Aguillo, Javier Valdivia, Alfredo Paredes, José Miguel Sánchez-Torres, Sergio Peralta Muñoz, Isidoro Barneto, Vanesa Gutierrez, Jesús Manuel Andrade Santiago, Francisco Aparisi, Dolores Isla, Santiago Ponce, David Vicente Baz, Angel Artal, Mariluz Amador, Mariano Provencio

المصدر: BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)

مصطلحات موضوعية: Clinical management, Chemotherapy, Epidermal growth factor receptor (EGFR) gene mutation, EGFR tyrosine kinase inhibitors (TKIs), Non-small-cell lung cancer (NSCLC), Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s12885-018-4004-7Test; https://doaj.org/toc/1471-2407Test

الوصول الحر: https://doaj.org/article/5d99fbd38d4248848d0a056c93027a23Test

المؤلفون: Rina Hui, Scott J. Antonia, Catherine Wadsworth, Suresh Senan, Bradford A. Perez, David Vicente, Davey B. Daniel, A. Villegas, Luis Paz-Ares, David R. Spigel, Mustafa Ozguroglu, Shuji Murakami, Corinne Faivre-Finn, Phillip A. Dennis, Helen Broadhurst, Corey J. Langer

المساهمون: Radiation Oncology, CCA - Cancer Treatment and quality of life

المصدر: Faivre-Finn, C, Spigel, D R, Senan, S, Langer, C, Perez, B A, Özgüroğlu, M, Daniel, D, Villegas, A, Vicente, D, Hui, R, Murakami, S, Paz-Ares, L, Broadhurst, H, Wadsworth, C, Dennis, P A & Antonia, S J 2021, ' Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC) ', Lung Cancer, vol. 151, pp. 30-38 . https://doi.org/10.1016/j.lungcan.2020.11.024Test
Lung Cancer, 151, 30-38. Elsevier Ireland Ltd
Faivre-finn, C, Spigel, D R, Senan, S, Langer, C, Perez, B A, Özgüroğlu, M, Daniel, D, Villegas, A, Vicente, D, Hui, R, Murakami, S, Paz-ares, L, Broadhurst, H, Wadsworth, C, Dennis, P A & Antonia, S J 2020, ' Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC) ', Lung Cancer . https://doi.org/10.1016/j.lungcan.2020.11.024Test

مصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, Cancer Research, medicine.medical_specialty, Randomization, Durvalumab, Lung Neoplasms, Pd-L1 Expression, Docetaxel, Placebo, Vinorelbine, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Median follow-up, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, Chemotherapy, Humans, Etoposide, Radiotherapy, business.industry, Antibodies, Monoclonal, Biomarker, Chemoradiotherapy, Concurrent, Carboplatin, Blockade, 030104 developmental biology, Nivolumab, Oncology, chemistry, 030220 oncology & carcinogenesis, Cell Lung-Cancer, Immunotherapy, Cisplatin, business, Non-small-cell lung cancer, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc66d1431e19641df7ad85c29d2fa5d3Test
https://research.vumc.nl/en/publications/a94e824c-5543-4cff-95c7-1dd8269a3f90Test

المؤلفون: Julien Mazieres, Balazs Halmos, David Vicente, Ali Tafreshi, Silvia Novello, Terufumi Kato, Bilal Piperdi, Jonathan Wilson, Mahmut Gumus, Jerónimo Rodríguez-Cid, Ki Hyeong Lee, Filiz Çay Şenler, Dariusz M. Kowalski, Shunichi Sugawara, Ying Cheng, Andrea Fülöp, Luis Paz-Ares, Keynote Investigators, Barbara Hermes, Alexander Luft, Gregory M. Lubiniecki, Tibor Csőszi, Xiaodong Li

المساهمون: Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Université Le Havre Normandie (ULH), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Université Le Havre Normandie (ULH), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)

المصدر: Transl Lung Cancer Res
The New England Journal of Medicine, 379, 2040-2051
The New England Journal of Medicine, 379, 21, pp. 2040-2051
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2018, 379 (21), pp.2040-2051. ⟨10.1056/NEJMoa1810865⟩

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Lung Neoplasms, [SDV]Life Sciences [q-bio], medicine.medical_treatment, Programmed Cell Death 1 Receptor, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Intention to Treat Analysis, Middle Aged, Paclitaxel, Progression-Free Survival, Survival Analysis, Pembrolizumab, chemistry.chemical_compound, 0302 clinical medicine, Monoclonal, 80 and over, Non-Small-Cell Lung, Humanized, General Medicine, 3. Good health, Editorial Commentary, 030220 oncology & carcinogenesis, medicine.medical_specialty, Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9], Antibodies, 03 medical and health sciences, Internal medicine, medicine, Carcinoma, Progression-free survival, Lung cancer, Survival analysis, Chemotherapy, business.industry, medicine.disease, respiratory tract diseases, 030104 developmental biology, chemistry, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b08d70d621daefa6515103b791d7d01Test
https://hdl.handle.net/10668/13017Test